

Serial#: 10/566,214  
INVENTOR SEARCH

=> FILE REG

FILE 'REGISTRY' ENTERED AT 18:31:38 ON 20 NOV 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 NOV 2009 HIGHEST RN 1192927-49-3  
DICTIONARY FILE UPDATES: 19 NOV 2009 HIGHEST RN 1192927-49-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

Uploading L2.str




Serial#: 10/566,214

chain nodes :  
11 12 13 14 15 22  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 16 17 18 19 20 21  
chain bonds :  
8-13 10-11 11-12 12-14 14-15 15-16 15-22  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 16-17 16-21 17-18 18-19  
19-20 20-21  
exact/norm bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-13 9-10 10-11 11-12 12-14  
14-15 15-16 15-22 16-17 16-21 17-18 18-19 19-20 20-21

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom  
22:CLASS

Uploading L5.str



chain nodes :  
11 12 13 14 15 22 23 24 25 26  
ring nodes :

# Serial#: 10/566,214

```

1  2  3  4  5  6  7  8  9  10  16  17  18  19  20  21
chain bonds :
8-13  10-11  11-12  12-14  12-23  14-15  15-16  15-22  19-26  23-24  23-25
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-10  7-8  8-9  9-10  16-17  16-21  17-18  18-19
19-20  20-21
exact/norm bonds :
5-7  6-10  7-8  8-9  8-13  9-10  12-14  14-15  15-22  23-24  23-25
exact bonds :
10-11  11-12  12-23  15-16  19-26
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-21  17-18  18-19  19-20  20-21

```


Match level :

```

1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS

```

Uploading L13.str



```

chain nodes :
11 12 13 14 15 22 23 24 25 26

```

**Serial#: 10/566,214**

ring nodes :  
1 2 3 4 5 6 7 8 9 10 16 17 18 19 20 21  
chain bonds :  
8-13 10-11 11-12 12-14 12-23 14-15 15-16 15-22 19-26 23-24 23-25  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 16-17 16-21 17-18 18-19  
19-20 20-21  
exact/norm bonds :  
5-7 6-10 7-8 8-9 8-13 9-10 12-14 14-15 15-22  
exact bonds :  
10-11 11-12 12-23 15-16 19-26  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21 23-24 23-25

Connectivity :  
12:3 E exact RC ring/chain  
Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom  
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS

**=> FILE HCAPLUS**

FILE 'HCAPLUS' ENTERED AT 18:31:46 ON 20 NOV 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Nov 2009 VOL 151 ISS 22  
FILE LAST UPDATED: 19 Nov 2009 (20091119/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/CAPLUS family databases for free! Complete details on the


**Serial#: 10/566,214**

number of free displays and other databases participating in this offer appear in NEWS 10.


'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

**=> D STAT QUE L30**

L2 STR



Page 1-A



Page 2-A

NODE ATTRIBUTES:


NSPEC	IS	R	AT	1
NSPEC	IS	R	AT	2
NSPEC	IS	R	AT	3
NSPEC	IS	R	AT	4


Serial#: 10/566,214

```
NSPEC   IS R      AT    5
NSPEC   IS R      AT    6
NSPEC   IS R      AT    7
NSPEC   IS R      AT    8
NSPEC   IS R      AT    9
NSPEC   IS R      AT   10
NSPEC   IS C      AT   11
NSPEC   IS C      AT   12
NSPEC   IS C      AT   13
NSPEC   IS C      AT   14
NSPEC   IS C      AT   15
NSPEC   IS R      AT   16
NSPEC   IS R      AT   17
NSPEC   IS R      AT   18
NSPEC   IS R      AT   19
NSPEC   IS R      AT   20
NSPEC   IS R      AT   21
NSPEC   IS C      AT   22
DEFAULT MLEVEL IS ATOM
MLEVEL   IS CLASS  AT   11 12 13 14 15 22
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE  
L4 99 SEA FILE=REGISTRY SSS FUL L2  
L5 STR





Page 2-A



Page 3-A

NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS C	AT	11
NSPEC	IS C	AT	12
NSPEC	IS C	AT	13
NSPEC	IS C	AT	14
NSPEC	IS C	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS C	AT	22
NSPEC	IS C	AT	23
NSPEC	IS C	AT	24
NSPEC	IS C	AT	25
NSPEC	IS C	AT	26

**Serial#: 10/566,214**

DEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 11 12 13 14 15 22 23 24 25 26

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 26


STEREO ATTRIBUTES: NONE

L7 60 SEA FILE=REGISTRY SUB=L4 SSS FUL L5

L13 STR



Page 1-A





1  
Cl 26

## NODE ATTRIBUTES:

HCOUNT	IS	M1	AT	4
HCOUNT	IS	M1	AT	7
HCOUNT	IS	M1	AT	14
HCOUNT	IS	M1	AT	24
NSPEC	IS	R	AT	1
NSPEC	IS	R	AT	2
NSPEC	IS	R	AT	3
NSPEC	IS	R	AT	4
NSPEC	IS	R	AT	5
NSPEC	IS	R	AT	6
NSPEC	IS	R	AT	7
NSPEC	IS	R	AT	8
NSPEC	IS	R	AT	9
NSPEC	IS	R	AT	10
NSPEC	IS	C	AT	11
NSPEC	IS	C	AT	12
NSPEC	IS	C	AT	13
NSPEC	IS	C	AT	14
NSPEC	IS	C	AT	15
NSPEC	IS	R	AT	16
NSPEC	IS	R	AT	17
NSPEC	IS	R	AT	18
NSPEC	IS	R	AT	19
NSPEC	IS	R	AT	20
NSPEC	IS	R	AT	21
NSPEC	IS	C	AT	22
NSPEC	IS	C	AT	23
NSPEC	IS	C	AT	24
NSPEC	IS	C	AT	25
NSPEC	IS	C	AT	26
CONNECT	IS	E3	RC	AT 12
DEFAULT	MLEVEL	IS	ATOM	
MLEVEL	IS	CLASS	AT	11 12 13 14 15 22 23 24 25 26
DEFAULT	ECLEVEL	IS	LIMITED	

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 26

## STEREO ATTRIBUTES: NONE

L14	35	SEA FILE=REGISTRY	SUB=L7	SSS	FUL	L13
L15	356	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L14
L16	57021	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	SALIVA+PFT/CT OR SALIVA?/BI
L17	11	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L16 (L) ACCELERATION/OBI
L18	1	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L15 AND L17
L19	630	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	XEROSTOMIA+OLD, PFT/CT
L20	2	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L15 AND L19

**Serial#: 10/566,214**

L23 112 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON NAGAMOTO H?/AU  
L24 78 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON KOHASHI M?/AU  
L25 1964 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON OKA H?/AU  
L26 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L15 AND L16  
L27 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L18 OR L20 OR L26  
L28 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L27 AND ((L23 OR L24  
OR L25))  
L29 1 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L23 AND L24 AND L25  
**L30 3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L28 OR L29**

**=> FILE MEDLINE**

FILE 'MEDLINE' ENTERED AT 18:32:00 ON 20 NOV 2009

FILE LAST UPDATED: 18 Nov 2009 (20091118/UP). FILE COVERS 1949 TO DATE.

MEDLINE and LMEDLINE have been updated with the 2009 Medical Subject Headings (MeSH) vocabulary and tree numbers from the U.S. National Library of Medicine (NLM). Additional information is available at

[http://www.nlm.nih.gov/pubs/techbull/nd08/nd08\\_medline\\_data\\_changes\\_2009.html](http://www.nlm.nih.gov/pubs/techbull/nd08/nd08_medline_data_changes_2009.html).

On February 21, 2009, MEDLINE was reloaded. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

**=> D STAT QUE L50**

L21 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "4-QUINOLINEPROPANOIC  
ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN  
L31 SEL PLU=ON L21 1- NAME : 4 TERMS  
L32 228 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L31  
L33 228 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L21 OR L32  
L34 26444 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON SALIVA/CT  
L37 3041 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON XEROSTOMIA/CT  
L40 1 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L33 AND L37  
L41 1 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L33 AND L34  
L42 1 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L40 OR L41  
L43 8594 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON "SJOGREN'S SYNDROME"/C  
T  
L44 3 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L33 AND L43  
L45 3 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L42 OR L44  
L46 34 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON NAGAMOTO H?/AU  
L47 19 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON KOHASHI M?/AU  
L48 932 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON OKA H?/AU  
**L50 2 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L45 AND ((L46 OR L47  
OR L48))**

**=> FILE WPIX BIOSIS**

FILE 'WPIX' ENTERED AT 18:32:54 ON 20 NOV 2009  
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'BIOSIS' ENTERED AT 18:32:54 ON 20 NOV 2009  
Copyright (c) 2009 The Thomson Corporation

**=> D STAT QUE L67**

L64 82 SEA NAGAMOTO H?/AU

Serial#: 10/566,214

L65 73 SEA KOHASHI M?/AU  
L66 3368 SEA OKA H?/AU  
L67 1 SEA L64 AND L65 AND L66

**=> FILE EMBASE**

FILE 'EMBASE' ENTERED AT 18:33:02 ON 20 NOV 2009  
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE COVERS 1974 TO 20 Nov 2009 (20091120/ED)

EMBASE was reloaded on March 30, 2008.

EMBASE is now updated daily. SDI frequency remains weekly (default)  
and biweekly.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE  
codes as part of the EMTREE thesaurus in EMBASE. Please update  
your current-awareness alerts (SDIs) if they contain EMTREE  
codes.

For further assistance, please contact your local helpdesk.

**=> D STAT QUE L85**

L21 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "4-QUINOLINEPROPANOIC  
ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN  
L68 SEL PLU=ON L21 1- NAME : 4 TERMS  
L69 381 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L68  
L70 381 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L21 OR L69  
L71 17167 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON XEROSTOMIA/CT  
L72 9448 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON SJOEGREN SYNDROME/CT  
L74 7 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L70 AND L71  
L75 12 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L70 AND L72  
L77 2 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L75 AND MANAGEMENT/TI  
L78 5 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L75 NOT (EYE OR  
RHEUMATOLOGIC)/TI  
L79 7 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L77 OR L78  
L80 9 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L74 OR L79  
L81 35 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON NAGAMOTO H?/AU  
L82 15 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON KOHASHI M?/AU  
L83 863 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON OKA H?/AU  
L85 2 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L80 AND (L81 OR L82 OR  
L83)

**=> DUP REMOVE L30 L50 L67 L85**

FILE 'HCAPLUS' ENTERED AT 18:33:28 ON 20 NOV 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 18:33:28 ON 20 NOV 2009

FILE 'WPIX' ENTERED AT 18:33:28 ON 20 NOV 2009  
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'EMBASE' ENTERED AT 18:33:28 ON 20 NOV 2009

Serial#: 10/566,214

Copyright (c) 2009 Elsevier B.V. All rights reserved.

PROCESSING COMPLETED FOR L30

PROCESSING COMPLETED FOR L50

PROCESSING COMPLETED FOR L67

PROCESSING COMPLETED FOR L85

L86 3 DUP REMOVE L30 L50 L67 L85 (5 DUPLICATES REMOVED)

ANSWERS '1-3' FROM FILE HCAPLUS

=> D L86 IBIB ABS HITSTR 1-3

**L86 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 1**

ACCESSION NUMBER: 2009:392963 HCAPLUS Full-text

DOCUMENT NUMBER: 151:395986

TITLE: Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjogren's syndrome: a double-blind placebo-controlled multicenter trial

AUTHOR(S): Sugai, Susumu; Takahashi, Hiroki; Ohta, Shuji; Nishinarita, Makoto; Takei, Masami; Sawada, Shigemasa; Yamaji, Ken; Oka, Hiroshi; Umehara, Hisanori; Koni, Ichiro; Sugiyama, Eiji; Nishiyama, Susumu; Kawakami, Atsushi

CORPORATE SOURCE: Kanazawa Medical University, Ishikawa, Japan

SOURCE: Modern Rheumatology (2009), 19(2), 114-124

CODEN: MROHA4; ISSN: 1439-7595

PUBLISHER: Springer Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effects of rebamipide on dry mouth and salivary secretion in Sjogren's syndrome patients were investigated in a double-blind placebo-controlled study. Rebamipide (100 mg TID) or placebo was administered for eight weeks and patient-assessed improvement of dry mouth and increase in salivary secretion measured by the Saxon test were evaluated. At two, four, and eight weeks, dry mouth improvement rates were, resp., 26.0%, 44.0%, and 46.9% for rebamipide and 20.0%, 27.1%, and 39.1% for placebo, and mean increases in salivary secretion were, resp., 0.14, 0.24, and 0.35 g for rebamipide and 0.03, 0.09, and 0.17 g for placebo, indicating higher values in the rebamipide group for both parameters at all timepoints but no significant differences between the two groups. Anal. by baseline characteristics suggested a statistically significant salivary secretion increasing effect of rebamipide in cases of primary Sjogren's syndrome. No difference in the incidence of adverse events was seen between the two groups, confirming the safety of rebamipide. As a salivary secretion increasing effect was strongly suggested in cases of primary Sjogren's syndrome, further study on the administration of rebamipide for the treatment of dry mouth in patients with Sjogren's syndrome is required.


IT 90098-04-7, Mucosta

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Mucosta was effective in increasing salivary secretion but had no effect on dry mouth symptoms in patient with Sjogren's syndrome)

RN 90098-04-7 HCAPLUS

CN 4-Quinolinepropanoic acid,  $\alpha$ -[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L86 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2008:292244 HCAPLUS Full-text

DOCUMENT NUMBER: 148:576370

TITLE: Effective treatment with oral administration of rebamipide in a mouse model of Sjogren's syndrome

AUTHOR(S): Kobashi, Masayuki; Ishimaru, Naozumi;

Arakaki, Rieko; Hayashi, Yoshio

CORPORATE SOURCE: University of Tokushima Graduate School, Tokushima, Japan

SOURCE: Arthritis & Rheumatism (2008), 58(2), 389-400

CODEN: ARHEAW; ISSN: 0004-3591

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Objective: To determine whether oral administration of rebamipide, a mucosal protective agent, is effective in the treatment of Sjogren's syndrome (SS) in the NFS/sld mouse model of the disease. Methods: NFS/sld mice were given daily oral doses of rebamipide (0.3 mg/kg of body weight or 3 mg/kg) or vehicle alone starting from the age of 4 wk to the age of 8 wk. The volume of saliva and tears was monitored during and after treatment. After the final dose, histol. features of the tissues, TUNEL + apoptotic duct cells in affected glands, T cell and cytokine function, and levels of Ig isotypes and serum autoantibodies were examined Results: The 3-mg/kg dose of rebamipide prevented the development of autoimmune lesions. The average volume of saliva in rebamipide-treated mice was significantly higher than that in control mice. We found decreased TUNEL + apoptotic duct cells in the salivary and lacrimal glands of rebamipide-treated mice as compared with control mice. Rebamipide treatment suppressed the activation of CD4 + T cells and Th1 cytokines (interleukin-2, interferon- $\gamma$ ) associated with impaired NF- $\kappa$ B activity. Production of serum autoantibodies, IgM, and IgG1 was clearly inhibited. Conclusion: Our findings demonstrate the efficacy of oral administration of rebamipide in the treatment of SS. Rebamipide represents a new therapeutic strategy for the treatment of patients with sicca symptoms caused by SS, as well as for patients with other diseases.

IT 90098-04-7, Rebamipide


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effective treatment with oral administration of rebamipide in mouse model of Sjogren's syndrome)

RN 90098-04-7 HCAPLUS

Serial#: 10/566,214

CN 4-Quinolinepropanoic acid,  $\alpha$ -[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L86 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2005:120780 HCAPLUS Full-text

DOCUMENT NUMBER: 142:183519

TITLE: Carbostyryl derivatives for accelerating salivation

INVENTOR(S): Nagamoto, Hisashi; Kohashi, Masayuki  
; Oka, Hiroshi

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan; St. Marianna University School of Medicine

SOURCE: PCT Int. Appl., 36 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011811	A1	20050210	WO 2004-JP9992	20040707
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1648563	A1	20060426	EP 2004-747458	20040707
EP 1648563	B1	20070919		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			

**Serial#: 10/566,214**

CN 1859948	A	20061108	CN 2004-80027975	20040707
JP 2006528662	T	20061221	JP 2006-521775	20040707
AT 373502	T	20071015	AT 2004-747458	20040707
KR 2006037408	A	20060503	KR 2006-701933	20060127
US 20070112026	A1	20070517	US 2006-566214	20060127
PRIORITY APPLN. INFO.:			JP 2003-282691	A 20030730
			JP 2004-21808	A 20040129
			WO 2004-JP9992	W 20040707

OTHER SOURCE(S): MARPAT 142:183519


AB An oral pharmaceutical composition for accelerating salivation and prophylaxis and/or treatment of xerostomia or hyposalivation comprises as an active ingredient a carbostyryl compound or a pharmaceutically acceptable salt thereof. For example, a mixture containing 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid (Rebamipide) 150 g, Avicel 40 g, corn starch 30 g, and magnesium stearate 2 g was tableted and film coated with a composition containing hydroxypropyl Me cellulose 10 g, polyethylene glycol 6000 3 g, castor oil 40 g, and methanol 40 g. Tablets containing 100 mg Rebamipide per tablet were orally administered three times per day immediately after a meal to patients having Sjogren's syndrome. An increase of salivation was observed with the effectiveness of 52.4% after 4 wk and 61.9% after 8 wk of administration.

IT 90098-04-7, Rebamipide

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(oral carbostyryl derivs. for accelerating salivation)

RN 90098-04-7 HCAPLUS

CN 4-Quinolinepropanoic acid,  $\alpha$ -[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Serial#: 10/566,214  
**STRUCTURE SEARCH**

**=> FILE HCAPLUS**

FILE 'HCAPLUS' ENTERED AT 18:33:53 ON 20 NOV 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Nov 2009 VOL 151 ISS 22  
FILE LAST UPDATED: 19 Nov 2009 (20091119/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.


During November, try the new LSUS format of legal status information in the CA/CAPLUS family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE


**=> D STAT QUE L53**

L2 STR





Page 1-A



Page 2-A

NODE ATTRIBUTES:


NSPEC	IS	R	AT	1
NSPEC	IS	R	AT	2
NSPEC	IS	R	AT	3
NSPEC	IS	R	AT	4
NSPEC	IS	R	AT	5
NSPEC	IS	R	AT	6
NSPEC	IS	R	AT	7
NSPEC	IS	R	AT	8
NSPEC	IS	R	AT	9
NSPEC	IS	R	AT	10

Serial#: 10/566,214


```
NSPEC   IS C      AT 11
NSPEC   IS C      AT 12
NSPEC   IS C      AT 13
NSPEC   IS C      AT 14
NSPEC   IS C      AT 15
NSPEC   IS R      AT 16
NSPEC   IS R      AT 17
NSPEC   IS R      AT 18
NSPEC   IS R      AT 19
NSPEC   IS R      AT 20
NSPEC   IS R      AT 21
NSPEC   IS C      AT 22
DEFAULT MLEVEL IS ATOM
MLEVEL   IS CLASS AT 11 12 13 14 15 22
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE  
L4 99 SEA FILE=REGISTRY SSS FUL L2  
L5 STR



Page 1-A



Page 2-A



Page 3-A

NODE ATTRIBUTES:

NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS R	AT	10
NSPEC	IS C	AT	11
NSPEC	IS C	AT	12
NSPEC	IS C	AT	13
NSPEC	IS C	AT	14
NSPEC	IS C	AT	15
NSPEC	IS R	AT	16
NSPEC	IS R	AT	17
NSPEC	IS R	AT	18
NSPEC	IS R	AT	19
NSPEC	IS R	AT	20
NSPEC	IS R	AT	21
NSPEC	IS C	AT	22
NSPEC	IS C	AT	23
NSPEC	IS C	AT	24
NSPEC	IS C	AT	25
NSPEC	IS C	AT	26

**Serial#: 10/566,214**

DEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 11 12 13 14 15 22 23 24 25 26

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 26


STEREO ATTRIBUTES: NONE

L7 60 SEA FILE=REGISTRY SUB=L4 SSS FUL L5

L13 STR



Page 1-A



Page 2-A

Cl 26

Page 3-A

## NODE ATTRIBUTES:

HCOUNT	IS	M1	AT	4
HCOUNT	IS	M1	AT	7
HCOUNT	IS	M1	AT	14
HCOUNT	IS	M1	AT	24
NSPEC	IS	R	AT	1
NSPEC	IS	R	AT	2
NSPEC	IS	R	AT	3
NSPEC	IS	R	AT	4
NSPEC	IS	R	AT	5
NSPEC	IS	R	AT	6
NSPEC	IS	R	AT	7
NSPEC	IS	R	AT	8
NSPEC	IS	R	AT	9
NSPEC	IS	R	AT	10
NSPEC	IS	C	AT	11
NSPEC	IS	C	AT	12
NSPEC	IS	C	AT	13
NSPEC	IS	C	AT	14
NSPEC	IS	C	AT	15
NSPEC	IS	R	AT	16
NSPEC	IS	R	AT	17
NSPEC	IS	R	AT	18
NSPEC	IS	R	AT	19
NSPEC	IS	R	AT	20
NSPEC	IS	R	AT	21
NSPEC	IS	C	AT	22
NSPEC	IS	C	AT	23
NSPEC	IS	C	AT	24
NSPEC	IS	C	AT	25
NSPEC	IS	C	AT	26
CONNECT	IS	E3	RC	AT 12
DEFAULT	MLEVEL	IS	ATOM	
MLEVEL	IS	CLASS	AT	11 12 13 14 15 22 23 24 25 26
DEFAULT	ECLEVEL	IS	LIMITED	

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 26

## STEREO ATTRIBUTES: NONE

L14	35	SEA FILE=REGISTRY	SUB=L7	SSS	FUL	L13
L15	356	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L14
L16	57021	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	SALIVA+PFT/CT OR SALIVA?/BI
L17	11	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L16 (L) ACCELERATION/OBI
L18	1	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L15 AND L17
L19	630	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	XEROSTOMIA+OLD, PFT/CT
L20	2	SEA FILE=HCAPLUS	SPE=ON	ABB=ON	PLU=ON	L15 AND L19

**Serial#: 10/566,214**

L26            3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L15 AND L16  
L27            3 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L18 OR L20 OR L26  
L51           3703 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON SJOGREN SYNDROME+OLD,P  
              FT/CT  
L52            4 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L15 AND L51  
**L53            4 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L27 OR L52**

**=> FILE MEDLINE**

FILE 'MEDLINE' ENTERED AT 18:34:11 ON 20 NOV 2009

FILE LAST UPDATED: 18 Nov 2009 (20091118/UP). FILE COVERS 1949 TO DATE.

MEDLINE and LMEDLINE have been updated with the 2009 Medical Subject Headings (MeSH) vocabulary and tree numbers from the U.S. National Library of Medicine (NLM). Additional information is available at

[http://www.nlm.nih.gov/pubs/techbull/nd08/nd08\\_medline\\_data\\_changes\\_2009.html](http://www.nlm.nih.gov/pubs/techbull/nd08/nd08_medline_data_changes_2009.html).

On February 21, 2009, MEDLINE was reloaded. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

**=> FILE HCAPLUS**

FILE 'HCAPLUS' ENTERED AT 18:34:19 ON 20 NOV 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Nov 2009 VOL151 ISS 22

FILE LAST UPDATED: 19 Nov 2009 (20091119/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/CAPLUS family databases for free! Complete details on the number of free displays and other databases participating in this

**Serial#: 10/566,214**

offer appear in NEWS 10.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

**=> S L53 NOT L30**

**L87 1 L53 NOT L30**

**=> FILE MEDLINE**

FILE 'MEDLINE' ENTERED AT 18:34:42 ON 20 NOV 2009

FILE LAST UPDATED: 18 Nov 2009 (20091118/UP). FILE COVERS 1949 TO DATE.

MEDLINE and LMEDLINE have been updated with the 2009 Medical Subject Headings (MeSH) vocabulary and tree numbers from the U.S. National Library of Medicine (NLM). Additional information is available at

[http://www.nlm.nih.gov/pubs/techbull/nd08/nd08\\_medline\\_data\\_changes\\_2009.html](http://www.nlm.nih.gov/pubs/techbull/nd08/nd08_medline_data_changes_2009.html).

On February 21, 2009, MEDLINE was reloaded. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

**=> D STAT QUE L45**

L21 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "4-QUINOLINEPROPANOIC  
ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN  
L31 SEL PLU=ON L21 1- NAME : 4 TERMS  
L32 228 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L31  
L33 228 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L21 OR L32  
L34 26444 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON SALIVA/CT  
L37 3041 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON XEROSTOMIA/CT  
L40 1 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L33 AND L37  
L41 1 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L33 AND L34  
L42 1 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L40 OR L41  
L43 8594 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON "SJOGREN'S SYNDROME"/C  
T  
L44 3 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L33 AND L43  
**L45 3 SEA FILE=MEDLINE SPE=ON ABB=ON PLU=ON L42 OR L44**

**=> S L45 NOT L50**

**L88 1 L45 NOT L50**

**=> FILE WPIX BIOSIS**

FILE 'WPIX' ENTERED AT 18:35:23 ON 20 NOV 2009

COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'BIOSIS' ENTERED AT 18:35:23 ON 20 NOV 2009

Copyright (c) 2009 The Thomson Corporation

**=> D STAT QUE L60**

L21 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "4-QUINOLINEPROPANOIC  
ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN  
L54 SEL PLU=ON L21 1- NAME : 4 TERMS  
L55 379 SEA L54  
L56 379 SEA L21 OR L55  
L57 3824 SEA SALIVA?(10A) (ACCEL? OR INCREAS?)  
L60 0 SEA L56(30A) L57

Serial#: 10/566,214

**=> D STAT QUE L62**

L21 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "4-QUINOLINEPROPANOIC  
ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN  
L54 SEL PLU=ON L21 1- NAME : 4 TERMS  
L55 379 SEA L54  
L56 379 SEA L21 OR L55  
L61 4470 SEA XEROSTO? OR DRY(3A) MOUTH?  
L62 0 SEA L56 AND L61

**=> FILE EMBASE**

FILE 'EMBASE' ENTERED AT 18:35:44 ON 20 NOV 2009  
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE COVERS 1974 TO 20 Nov 2009 (20091120/ED)

EMBASE was reloaded on March 30, 2008.

EMBASE is now updated daily. SDI frequency remains weekly (default)  
and biweekly.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE  
codes as part of the EMTREE thesaurus in EMBASE. Please update  
your current-awareness alerts (SDIs) if they contain EMTREE  
codes.

For further assistance, please contact your local helpdesk.

**=> D STAT QUE L80**

L21 1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "4-QUINOLINEPROPANOIC  
ACID, A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN  
L68 SEL PLU=ON L21 1- NAME : 4 TERMS  
L69 381 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L68  
L70 381 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L21 OR L69  
L71 17167 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON XEROSTOMIA/CT  
L72 9448 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON SJOEGREN SYNDROME/CT  
L74 7 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L70 AND L71  
L75 12 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L70 AND L72  
L77 2 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L75 AND MANAGEMENT/TI  
L78 5 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L75 NOT (EYE OR  
RHEUMATOLOGIC)/TI  
L79 7 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L77 OR L78  
L80 9 SEA FILE=EMBASE SPE=ON ABB=ON PLU=ON L74 OR L79

**=> S L80 NOT L85**

L89 7 L80 NOT L85

**=> DUP REMOVE L87 L88 L89**

FILE 'HCAPLUS' ENTERED AT 18:36:18 ON 20 NOV 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 18:36:18 ON 20 NOV 2009



Serial#: 10/566,214

FILE 'EMBASE' ENTERED AT 18:36:18 ON 20 NOV 2009  
Copyright (c) 2009 Elsevier B.V. All rights reserved.  
PROCESSING COMPLETED FOR L87  
PROCESSING COMPLETED FOR L88  
PROCESSING COMPLETED FOR L89

L90 8 DUP REMOVE L87 L88 L89 (1 DUPLICATE REMOVED)

ANSWER '1' FROM FILE HCAPLUS  
ANSWER '2' FROM FILE MEDLINE  
ANSWERS '3-8' FROM FILE EMBASE

L90 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:1267017 HCAPLUS Full-text  
DOCUMENT NUMBER: 151:478529  
TITLE: Topical LFA-1 antagonists for use in localized  
treatment of immune related disorders  
INVENTOR(S): Burnier, John; Gadek, Thomas  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 85pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090258070	A1	20091015	US 2009-386359	20090415
WO 2009128934	A1	20091022	WO 2009-US2389	20090415
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2008-45240P P 20080415

AB This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 topical formulations of the present invention.

INCL 424489000; 514314000; 514311000; 514300000; 514448000; 514009000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1

IT Alopecia

Angiogenesis inhibitors  
Anti-inflammatory agents  
Antiarthritics  
Antiasthmatics  
Antimicrobial agents  
Antioxidants  
Antirheumatic agents  
Antiulcer agents  
Antiviral agents

Arthralgia  
Asthma  
Beeswax  
Blood plasma  
Chelating agents  
Chronic obstructive pulmonary disease  
Complexing agents  
Crohn disease  
Eczema  
Edema  
Emulsions  
Graves' disease  
Human  
Immune disease  
Immunomodulators  
Lubricants  
Oral drug delivery systems  
Permeation enhancers  
Pharmaceutical creams  
Pharmaceutical emulsions  
Pharmaceutical foams  
Pharmaceutical gels  
Pharmaceutical ointments  
Pharmaceutical pastes  
Pharmaceutical powders  
Pharmaceutical solutions  
Pharmaceutical sprays  
Pharmaceutical suspensions  
Psoriasis  
Pulmonary fibrosis  
Retinal disease  
Retinitis  
Rheumatoid arthritis  
    Sjogren syndrome  
Surfactants  
T cell  
Topical drug delivery systems  
Ulcerative colitis  
Uveitis  
Volatile substances  
Wetting agents

(topical LFA-1 antagonists for use in localized treatment of immune related disorders)

IT 59865-13-3, Cyclosporine 59985-21-6, Diquafosol 90098-04-7,  
Rebamipide 245466-70-0 851784-48-0 851784-50-4 851784-54-8  
851784-56-0 851784-64-0 851784-72-0 915397-46-5 915397-52-3  
915397-63-6 915397-90-9 915397-99-8 1025967-78-5 1026240-04-9  
1148048-06-9 1148048-11-6 1148048-14-9 1148048-17-2 1148048-24-1  
1148048-27-4 1148048-29-6 1148048-36-5 1148048-38-7

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)

(topical LFA-1 antagonists for use in localized treatment of immune related disorders)

IT 90098-04-7, Rebamipide


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)

(topical LFA-1 antagonists for use in localized treatment of immune related disorders)

RN 90098-04-7 HCAPLUS

CN 4-Quinolinepropanoic acid,  $\alpha$ -[(4-chlorobenzoyl)amino]-1,2-dihydro-2-

oxo- (CA INDEX NAME)



L90 ANSWER 2 OF 8 MEDLINE on STN DUPLICATE 1  
 ACCESSION NUMBER: 2009123510 MEDLINE Full-text  
 DOCUMENT NUMBER: PubMed ID: 18841440  
 TITLE: Sjogren's syndrome: promising, new treatment options besides nizatidine.  
 AUTHOR: Kapoor Shailendra  
 SOURCE: Modern rheumatology / the Japan Rheumatism Association, (2009) Vol. 19, No. 1, pp. 100-1. Electronic Publication: 2008-10-08.  
 COMMENT: Journal code: 100959226. ISSN: 1439-7595.  
 Comment on: Mod Rheumatol. 2008;18(5):455-9. PubMed ID: 18478182  
 PUB. COUNTRY: Japan  
 DOCUMENT TYPE: Commentary  
 Letter  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200906  
 ENTRY DATE: Entered STN: 10 Feb 2009  
 Last Updated on STN: 2 Jul 2009  
 Entered Medline: 30 Jun 2009  
 CONTROLLED TERM: \*Alanine: AA, analogs & derivatives  
 Alanine: TU, therapeutic use  
 Antioxidants: TU, therapeutic use  
 \*Flax  
 Histamine H2 Antagonists: TU, therapeutic use  
 Humans  
 \*Nizatidine: TU, therapeutic use  
 \*Plant Preparations: TU, therapeutic use  
 \*Quinolones: TU, therapeutic use  
 \*Seeds  
 \*Sjogren's Syndrome: DT, drug therapy  
 Treatment Outcome  
 CAS REGISTRY NO.: 111911-87-6 (rebamipide); 56-41-7 (Alanine);  
 76963-41-2 (Nizatidine)  
 CHEMICAL NAME: 0 (Antioxidants); 0 (Histamine H2 Antagonists); 0 (Plant

Preparations); 0 (Quinolones)

L90 ANSWER 3 OF 8 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2008439484 EMBASE Full-text  
 TITLE: Rebamipide as an important adjunctive tool in the management of rheumatologic disorders: Comment on the article by Kohashi et al.  
 AUTHOR: Kapoor, Shailendra, Dr. (correspondence)  
 CORPORATE SOURCE: University of Illinois at Chicago.  
 SOURCE: Arthritis and Rheumatism, (September 2008) Vol. 58, No. 9, pp. 2923.  
 Refs: 9  
 ISSN: 0004-3591 CODEN: ARHEAW  
 PUBLISHER: John Wiley and Sons Inc., P.O.Box 18667, Newark, NJ 07191-8667, United States.  
 COUNTRY: United States  
 DOCUMENT TYPE: Journal; Letter  
 FILE SEGMENT: 031 Arthritis and Rheumatism  
 037 Drug Literature Index  
 LANGUAGE: English  
 ENTRY DATE: Entered STN: 17 Oct 2008  
 Last Updated on STN: 17 Oct 2008  
 CONTROLLED TERM: Medical Descriptors:  
 angiogenesis  
 aphthous ulcer: DT, drug therapy  
 Behcet disease  
 digestive system ulcer: DT, drug therapy  
 digestive system ulcer: PC, prevention  
 drug efficacy  
 human  
 letter  
 priority journal  
 \*rheumatic disease: DT, drug therapy  
 Sjogren syndrome: DT, drug therapy  
 ulcerative colitis: DT, drug therapy  
 xerostomia: DT, drug therapy  
 CONTROLLED TERM: Drug Descriptors:  
 misoprostol: CM, drug comparison  
 nonsteroid antiinflammatory agent  
 \*rebamipide: CM, drug comparison  
 \*rebamipide: DT, drug therapy  
 \*rebamipide: PD, pharmacology  
 CAS REGISTRY NO.: (misoprostol) 59122-46-2, 59122-48-4; (rebamipide)  
 ) 111911-87-6

L90 ANSWER 4 OF 8 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2008502560 EMBASE Full-text  
 TITLE: Treatment of Dry Eye Disease by the Non-Ophthalmologist.  
 AUTHOR: Foulks, Gary N., Dr. (correspondence)  
 CORPORATE SOURCE: Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, 301 East Muhammad Ali Boulevard, Louisville, KY 40202, United States. gnfoul01@louisville.edu  
 SOURCE: Rheumatic Disease Clinics of North America, (November 2008) Vol. 34, No. 4, pp. 987-1000.  
 Refs: 72

**Serial#: 10/566,214**

ISSN: 0889-857X CODEN: RDCAEK  
PUBLISHER: W.B. Saunders, Independence Square West, Philadelphia, PA  
19106-3399, United States.  
PUBLISHER IDENT.: S 0889-857X(08)00079-3  
COUNTRY: United States  
DOCUMENT TYPE: Journal; General Review; (Review)  
FILE SEGMENT: 012 Ophthalmology  
031 Arthritis and Rheumatism  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 3 Dec 2008  
Last Updated on STN: 3 Dec 2008

ABSTRACT: Physicians caring for patients who have Sjogren's syndrome often face a particularly difficult task in managing the dry eye that occurs with this disease. The discomfort produced by the condition and the fluctuation of vision attendant to tear film instability are often the most annoying of the clinical symptoms. The understanding of dry eye disease in both its clinical expression and underlying etiopathology has expanded over the past 10 years with implications for management and therapy. The array of potential treatments both topical and systemic has evolved to provide a much more targeted and effective arsenal from which the clinician may choose. .COPYRGT. 2008 Elsevier Inc. All rights reserved.

CONTROLLED TERM: Medical Descriptors:  
antiinflammatory activity  
cataract: SI, side effect  
clinical trial  
disease classification  
disease severity  
drug efficacy  
\*dry eye: DT, drug therapy  
\*dry eye: ET, etiology  
\*dry eye: SU, surgery  
\*dry eye: TH, therapy  
eye inflammation: DT, drug therapy  
glaucoma: SI, side effect  
hormonal therapy  
human  
keratoconjunctivitis sicca: DT, drug therapy  
lacrimation  
pathogenesis  
priority journal  
review  
rosacea: DT, drug therapy  
sebaceous gland disease: DT, drug therapy  
serum  
Sjogren syndrome  
superinfection: SI, side effect  
treatment outcome  
xerostomia: DT, drug therapy

CONTROLLED TERM: Drug Descriptors:  
12 sulfodehydroabiatic acid: CT, clinical trial  
12 sulfodehydroabiatic acid: DT, drug therapy  
12 sulfodehydroabiatic acid: TP, topical drug  
administration  
acetylcysteine: DT, drug therapy  
acetylcysteine: TP, topical drug administration  
antiinflammatory agent: DT, drug therapy  
artificial tear: DT, drug therapy

**Serial#: 10/566,214**

artificial tear: TP, topical drug administration  
cevimeline: DT, drug therapy  
cevimeline: PO, oral drug administration  
corticosteroid: CB, drug combination  
corticosteroid: DT, drug therapy  
corticosteroid: TP, topical drug administration  
cyclosporin A: AE, adverse drug reaction  
cyclosporin A: CB, drug combination  
cyclosporin A: DT, drug therapy  
cyclosporin A: PD, pharmacology  
cyclosporin A: TP, topical drug administration  
diquafosol: CT, clinical trial  
diquafosol: DT, drug therapy  
diquafosol: TP, topical drug administration  
estratest: DT, drug therapy  
estrogen: DT, drug therapy  
estrogen: TP, topical drug administration  
eye drops: DT, drug therapy  
eye drops: TP, topical drug administration  
idestrin estradiol  
immunomodulating agent: DT, drug therapy  
immunomodulating agent: TP, topical drug administration  
lipid emulsion: CT, clinical trial  
lipid emulsion: DT, drug therapy  
lipid emulsion: TP, topical drug administration  
loteprednol etabonate: DT, drug therapy  
loteprednol etabonate: TP, topical drug administration  
lubricating agent: CB, drug combination  
lubricating agent: DT, drug therapy  
lubricating agent: TP, topical drug administration  
omega 3 fatty acid: CB, drug combination  
omega 3 fatty acid: DT, drug therapy  
omega 3 fatty acid: PO, oral drug administration  
omega 3 fatty acid: TP, topical drug administration  
optive  
pilocarpine: CT, clinical trial  
pilocarpine: DT, drug therapy  
pilocarpine: PO, oral drug administration  
    rebamipide: CT, clinical trial  
    rebamipide: DT, drug therapy  
    rebamipide: TP, topical drug administration  
refresh endura  
soothe  
steroid: AE, adverse drug reaction  
steroid: DT, drug therapy  
steroid: TP, topical drug administration  
systane  
testosterone: CT, clinical trial  
testosterone: DT, drug therapy  
testosterone: TP, topical drug administration  
tetracycline: DT, drug therapy  
theratears nutrition  
unclassified drug

SUPPLEMENTARY TERM: Cyclosporine; Dry eye; Secretagogues; Sjogren's syndrome  
CAS REGISTRY NO.: (12 sulfodehydroabiatic acid) 33159-27-2, 86408-72-2;  
(acetylcysteine) 616-91-1; (cevimeline) 107220-27-9,  
107220-28-0, 107233-08-9, 153504-70-2; (cyclosporin A)  
59865-13-3, 63798-73-2; (diquafosol) 211427-08-6;  
(loteprednol etabonate) 82034-46-6; (pilocarpine) 148-72-1,  
54-71-7, 92-13-7; (rebamipide)  
111911-87-6; (testosterone) 58-22-0; (tetracycline)

**Serial#: 10/566,214**

CHEMICAL NAME: 23843-90-5, 60-54-8, 64-75-5  
(1) estratest; (2) evoxac; (3) idestrin estradiol; (4) lotemax; (5) optive; (6) refresh endura; (7) restasis; (8) salagen; (9) soothe; (10) systane; (11) theratears nutrition

COMPANY NAME: (1) Solvay (United States); (2) Daiichi Seiyaku (United States); (3) nascent (United States); (4) Bausch and Lomb (United States); (5) Allergan (United States); (6) Allergan (United States); (7) Allergan (United States); (8) MGI (United States); (9) Bausch and Lomb (United States); (10) Alcon (United States); (11) advanced research (United States); Inspire (United States); Novartis (United States); Otsuka (United States)

L90 ANSWER 5 OF 8 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2008312638 EMBASE Full-text

TITLE: Current and prospective treatment options for Sjogren,s syndrome.

AUTHOR: Sugai, Susumu, Dr. Prof. (correspondence)

CORPORATE SOURCE: Kudo General Hospital, Kanazawa Medical University, Kanazawa, Japan. sussugai@helen.ocn.ne.jp

AUTHOR: Masaki, Yasafumi

CORPORATE SOURCE: Department of Hematology and Immunology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan. yasum@kanazawa-med.ac.jp

AUTHOR: Sugai, Susumu, Dr. Prof. (correspondence)

CORPORATE SOURCE: Kudo General Hospital, Kanazawa University, Kanazawa, Japan . sussugai@helen.ocn.ne.jp

SOURCE: Expert Review of Clinical Immunology, (Jul 2008) Vol. 4, No. 4, pp. 469-479.  
Refs: 87  
ISSN: 1744-666X

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; General Review; (Review)

FILE SEGMENT: 011 Otorhinolaryngology  
012 Ophthalmology  
026 Immunology, Serology and Transplantation  
030 Clinical and Experimental Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 10 Jul 2008  
Last Updated on STN: 10 Jul 2008

ABSTRACT: Sjogren's syndrome is both an organ-specific and a systemic autoimmune disease. Patients with dry eyes and dry mouth usually receive symptomatic treatment. Topical cyclosporine A may be administered to patients with dry eyes. The efficacy of muscarinic agonists, such as pilocarpine and cevimeline, in increasing salivary and lacrimal flow and improving patient symptoms has been well documented. Mild immunomodulatory or immunosuppressive medication is preferable to prevent the mild progressive course of the disorders. Other patients who show aggressive progression to organ disorders should be managed differently. High doses of corticosteroids, immunosuppressive agents or new biological agents, such as antibodies to CD20, are required for these patients. The elimination of B lymphocytes by anti-CD20 antibodies may be highly beneficial; however, the development of more selective drugs based on the pathogenesis of the disease is required for the future treatment of Sjogren's syndrome. .COPYRG. 2008 Expert Reviews Ltd.

CONTROLLED TERM: Medical Descriptors:

**Serial#: 10/566,214**

abdominal pain: SI, side effect  
B lymphocyte  
clinical trial  
disease course  
drug dose comparison  
drug dose increase  
drug efficacy  
drug induced headache: SI, side effect  
drug mechanism  
drug megadose  
drug safety  
drug selectivity  
drug targeting  
drug tolerability  
dry eye: DT, drug therapy  
dry eye: SU, surgery  
human  
immunopathogenesis  
keratoconjunctivitis sicca: DT, drug therapy  
keratoconjunctivitis sicca: SU, surgery  
low drug dose  
monotherapy  
mucosa associated lymphoid tissue lymphoma: DT, drug therapy  
nausea: SI, side effect  
nonhuman  
plasmapheresis  
recommended drug dose  
regulatory T lymphocyte  
review  
salivation  
side effect: SI, side effect  
    \*Sjogren syndrome: DT, drug therapy  
    \*Sjogren syndrome: ET, etiology  
sweating  
tear flow  
unspecified side effect: SI, side effect  
vasculitis: DT, drug therapy  
vasculitis: TH, therapy  
viral gene delivery system  
viral gene therapy  
    xerostomia: DT, drug therapy

CONTROLLED TERM: Drug Descriptors:  
alpha interferon: CT, clinical trial  
alpha interferon: DO, drug dose  
alpha interferon: DT, drug therapy  
alpha interferon: PO, oral drug administration  
alpha interferon: PD, pharmacology  
antirheumatic agent: DT, drug therapy  
aquaporin 1: DT, drug therapy  
artificial tear: DT, drug therapy  
CD20 antibody: DT, drug therapy  
CD40 ligand monoclonal antibody: DT, drug therapy  
CD40 ligand monoclonal antibody: IP, intraperitoneal drug administration  
CD40 ligand monoclonal antibody: PD, pharmacology  
cevimeline: AE, adverse drug reaction  
cevimeline: CT, clinical trial  
cevimeline: DO, drug dose  
cevimeline: DT, drug therapy  
cevimeline: PO, oral drug administration



**Serial#: 10/566,214**

cevimeline: PD, pharmacology  
corticosteroid: CB, drug combination  
corticosteroid: DO, drug dose  
corticosteroid: DT, drug therapy  
corticosteroid: PO, oral drug administration  
cyclophosphamide: CB, drug combination  
cyclophosphamide: DT, drug therapy  
cyclophosphamide: IV, intravenous drug administration  
cyclosporin A: DT, drug therapy  
cyclosporin A: TP, topical drug administration  
doxorubicin: CB, drug combination  
doxorubicin: DT, drug therapy  
etanercept: CT, clinical trial  
etanercept: DT, drug therapy  
gefarnate: DT, drug therapy  
gefarnate: PD, pharmacology  
hydroxychloroquine: DT, drug therapy  
hydroxychloroquine: PD, pharmacology  
immunomodulating agent: DT, drug therapy  
immunosuppressive agent: DT, drug therapy  
infliximab: CT, clinical trial  
infliximab: DT, drug therapy  
interleukin 10: DT, drug therapy  
interleukin 10: PD, pharmacology  
mizoribine: AE, adverse drug reaction  
mizoribine: CT, clinical trial  
mizoribine: DT, drug therapy  
mizoribine: PD, pharmacology  
muscarinic agent: DT, drug therapy  
parvovirus vector  
pilocarpine: AE, adverse drug reaction  
pilocarpine: CT, clinical trial  
pilocarpine: DO, drug dose  
pilocarpine: DT, drug therapy  
pilocarpine: PO, oral drug administration  
pilocarpine: PD, pharmacology  
pilocarpine: SC, subcutaneous drug administration  
placebo  
prednisolone: DT, drug therapy  
prednisone: CB, drug combination  
prednisone: DT, drug therapy  
    rebamipide: AE, adverse drug reaction  
    rebamipide: CT, clinical trial  
    rebamipide: DT, drug therapy  
    rebamipide: PO, oral drug administration  
    rebamipide: PD, pharmacology  
rituximab: CT, clinical trial  
rituximab: CB, drug combination  
rituximab: DO, drug dose  
rituximab: DT, drug therapy  
sni 2011  
tumor necrosis factor alpha inhibitor: DT, drug therapy  
unindexed drug  
vincristine: CB, drug combination  
vincristine: DT, drug therapy

CAS REGISTRY NO.: (aquaporin 1) 146410-94-8, 149348-86-7; (cevimeline)  
107220-27-9, 107220-28-0, 107233-08-9, 153504-70-2;  
(cyclophosphamide) 50-18-0; (cyclosporin A) 59865-13-3,  
63798-73-2; (doxorubicin) 23214-92-8, 25316-40-9;  
(etanercept) 185243-69-0, 200013-86-1; (gefarnate) 51-77-4;  
(hydroxychloroquine) 118-42-3, 525-31-5; (infliximab)

**Serial#: 10/566,214**

170277-31-3; (mizoribine) 50924-49-7; (pilocarpine)  
148-72-1, 54-71-7, 92-13-7; (prednisolone) 50-24-8;  
(prednisone) 53-03-2; (rebamipide)  
111911-87-6; (rituximab) 174722-31-7; (vincristine)  
57-22-7

CHEMICAL NAME: sni 2011

L90 ANSWER 6 OF 8 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2008131921 EMBASE Full-text  
TITLE: Primary Sjogren's Syndrome: Current and Prospective Therapies.  
AUTHOR: Thanou-Stavraki, Aikaterini; James, Judith A., Dr. (correspondence)  
CORPORATE SOURCE: Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States. jamesj@omrf.ouhsc.edu  
AUTHOR: Thanou-Stavraki, Aikaterini; James, Judith A., Dr. (correspondence)  
CORPORATE SOURCE: Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. jamesj@omrf.ouhsc.edu  
AUTHOR: James, Judith A., Dr. (correspondence)  
CORPORATE SOURCE: Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. jamesj@omrf.ouhsc.edu  
SOURCE: Seminars in Arthritis and Rheumatism, (Apr 2008) Vol. 37, No. 5, pp. 273-292.  
Refs: 251  
ISSN: 0049-0172 CODEN: SAHRBF  
PUBLISHER IDENT.: S 0049-0172(07)00113-8  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT: 031 Arthritis and Rheumatism  
037 Drug Literature Index  
038 Adverse Reactions Titles  
006 Internal Medicine  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 7 Apr 2008  
Last Updated on STN: 7 Apr 2008

ABSTRACT: Objective: To summarize data on existing and experimental therapies for primary Sjogren's syndrome (pSS), referring both to sicca syndrome and to other systemic disease manifestations. Methods: Relevant English and non-English articles acquired through Medline were reviewed. Results: pSS usually has a benign clinical course, centered on sicca features and general musculoskeletal manifestations, and is managed symptomatically. However, a subset of patients develops more severe extraglandular disease that warrants close monitoring and aggressive treatment. For dry eyes and mouth, nonpharmacologic measures to preserve secretions, and tear and saliva substitutes, offer some symptomatic relief. Muscarinic agonists and topical cyclosporine yield well-documented improvement in ocular sicca features. Although traditional antirheumatic drugs are used empirically for polyarthritis and other Sjogren's symptoms, their efficacy in pSS overall and as disease-modifying agents is limited. For the potential severe, nonexocrine manifestations complicating pSS, standard high-dose immunosuppression is used. Among the biologic agents already examined in pSS, those targeting tumor necrosis factor (TNF)- $\alpha$  failed to demonstrate significant benefit. Nonetheless, rituximab and other B-cell-depleting therapies appear promising. Conclusions: Treatment of pSS patients with severe extraglandular disease

should differ from that of patients with predominantly sicca features and/or general musculoskeletal manifestations. pSS treatment is mainly symptomatic, primarily directed against sicca complaints. The traditional anti-rheumatic agents show limited efficacy in the systemic process and use of systemic TNF- $\alpha$  inhibitors has been very disappointing. B cell depleting treatments and other newer biologic therapies appear more promising. .COPYRGHT. 2008 Elsevier Inc. All rights reserved.

CONTROLLED TERM: Medical Descriptors:  
antiinflammatory activity  
article  
atopic dermatitis: DT, drug therapy  
B cell lymphoma  
clinical feature  
clinical trial  
disease severity  
drug efficacy  
drug indication  
drug safety  
dry eye: DT, drug therapy  
dry eye: SI, side effect  
eye discharge: DT, drug therapy  
glomerulonephritis  
hematologic disease  
human  
immunosuppressive treatment  
keratoconjunctivitis sicca: SU, surgery  
lacrimal gland disease: DT, drug therapy  
lacrimation  
low drug dose  
lymphocyte depletion  
MEDLINE  
menopausal syndrome: DT, drug therapy  
neurologic disease  
patient monitoring  
polyarthritis: DT, drug therapy  
priority journal  
salivation  
    \*Sjogren syndrome: DT, drug therapy  
topical treatment  
treatment outcome  
vasculitis  
viral gene delivery system  
    xerostomia: DT, drug therapy  
    xerostomia: TH, therapy

CONTROLLED TERM: Drug Descriptors:  
12 sulfodehydroabietic acid: DT, drug therapy  
alpha interferon: DO, drug dose  
alpha interferon: DT, drug therapy  
alpha interferon: PO, oral drug administration  
alpha interferon: PA, parenteral drug administration  
alpha interferon: PD, pharmacology  
antihistaminic agent: AE, adverse drug reaction  
antiinflammatory agent: DT, drug therapy  
antirheumatic agent: DT, drug therapy  
beta adrenergic receptor blocking agent: AE, adverse drug reaction  
cevimeline: CM, drug comparison  
cevimeline: DT, drug therapy  
corticosteroid: DT, drug therapy

**Serial#: 10/566,214**

corticosteroid: TP, topical drug administration  
cyclosporin A: CT, clinical trial  
cyclosporin A: CR, drug concentration  
cyclosporin A: DT, drug therapy  
cyclosporin A: PK, pharmacokinetics  
cyclosporin A: PD, pharmacology  
cyclosporin A: TP, topical drug administration  
diquafosol: DT, drug therapy  
diquafosol: PD, pharmacology  
diquafosol: TP, topical drug administration  
disease modifying antirheumatic drug: DT, drug therapy  
diuretic agent: AE, adverse drug reaction  
estradiol: DT, drug therapy  
eye drops: DT, drug therapy  
eye drops: TP, topical drug administration  
gefarnate: DT, drug therapy  
immunosuppressive agent: DT, drug therapy  
muscarinic agent: DT, drug therapy  
nonsteroid antiinflammatory agent: DT, drug therapy  
nonsteroid antiinflammatory agent: TP, topical drug administration  
pilocarpine: CM, drug comparison  
pilocarpine: DT, drug therapy  
pimecrolimus: DT, drug therapy  
pimecrolimus: TP, topical drug administration  
rebamipide: DT, drug therapy  
recombinant interleukin 10: DT, drug therapy  
rituximab: DT, drug therapy  
tacrolimus: DT, drug therapy  
tacrolimus: TP, topical drug administration  
testosterone: DT, drug therapy  
testosterone: TP, topical drug administration  
testosterone: TD, transdermal drug administration  
tricyclic antidepressant agent: AE, adverse drug reaction  
tumor necrosis factor alpha: EC, endogenous compound  
tumor necrosis factor alpha receptor: DT, drug therapy  
unindexed drug  
vasoactive intestinal polypeptide: DT, drug therapy  
vasoactive intestinal polypeptide: PD, pharmacology

CAS REGISTRY NO.: (12 sulfodehydroabiatic acid) 33159-27-2, 86408-72-2;  
(cevimeline) 107220-27-9, 107220-28-0, 107233-08-9,  
153504-70-2; (cyclosporin A) 59865-13-3, 63798-73-2;  
(diquafosol) 211427-08-6; (gefarnate) 51-77-4;  
(pilocarpine) 148-72-1, 54-71-7, 92-13-7; (pimecrolimus)  
137071-32-0; (rebamipide) 111911-87-6;  
(rituximab) 174722-31-7; (tacrolimus) 104987-11-3;  
(testosterone) 58-22-0; (vasoactive intestinal polypeptide)  
37221-79-7

CHEMICAL NAME: (1) evoxac; (2) restasis; (3) salagen; evoxac  
COMPANY NAME: (1) Daiichi Seiyaku (United States); (2) Allergan (United States); (3) Novartis (United States)

L90 ANSWER 7 OF 8 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2008073013 EMBASE Full-text

TITLE: Pharmacological management of dry eye in the elderly patient.

AUTHOR: Foulks, Gary N., Dr. Prof. (correspondence)

CORPORATE SOURCE: Department of Ophthalmology and Vision Science, University of Louisville School of Medicine, Louisville, KY, United States.

**Serial#: 10/566,214**

AUTHOR: Foulks, Gary N., Dr. Prof. (correspondence)  
CORPORATE SOURCE: 301 E. Muhammad Ali Boulevard, Louisville, KY 40202, United States.  
SOURCE: Drugs and Aging, (2008) Vol. 25, No. 2, pp. 105-118.  
Refs: 98  
ISSN: 1170-229X CODEN: DRAGE6  
COUNTRY: New Zealand  
DOCUMENT TYPE: Journal; General Review; (Review)  
FILE SEGMENT: 012 Ophthalmology  
017 Public Health, Social Medicine and Epidemiology  
020 Gerontology and Geriatrics  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 6 Mar 2008  
Last Updated on STN: 6 Mar 2008

ABSTRACT: Dry eye disease is a common and increasingly prevalent condition particularly associated with advancing age and postmenopausal women.

Epidemiological studies identify prevalence rates ranging from 7% in the US to 33% in the Asian population. Research increasingly identifies risk factors of increasing age, female sex, smoking, use of video display terminals and use of certain medications as well as environmental stresses as aggravating factors for the disease. Basic and clinical investigations provide cumulative evidence of hyperosmolarity of the tear film and ocular surface/lacrimal gland inflammation as pathogenic features of dry eye disease. A decline in systemic and local levels of sex hormones is associated with advancing age and advancing disease. Pharmacological therapeutic interventions include enhanced lubricants and anti-inflammatory drugs such as topical corticosteroids and ciclosporin (cyclosporine A). Secretagogues and hormonal supplementation are potential future therapies. The increased understanding of the contributing and pathogenetic factors responsible for dry eye provides a rationale for multiple therapeutic options for this multi-factorial disease. In the elderly patient it is important to recognize the physical and cognitive limitations that will influence the selection of appropriate topical medication. .COPYRGHT. 2008 Adis Data Information BV. All rights reserved.

CONTROLLED TERM: Medical Descriptors:  
Asian  
cataract: SI, side effect  
clinical trial  
cognition  
\*dry eye: DT, drug therapy  
\*dry eye: EP, epidemiology  
elderly care  
emulsion  
environmental exposure  
fluorescence  
Hispanic  
hormone substitution  
human  
inflammation  
intraocular pressure  
lubrication  
multifactorial genetic disorder  
nonhuman  
osmolarity  
prevalence  
priority journal  
review  
risk factor

**Serial#: 10/566,214**

sex difference  
side effect: SI, side effect  
social behavior  
staining  
tear film  
xerostomia: DT, drug therapy

**CONTROLLED TERM:**

Drug Descriptors:  
12 sulfodehydroabiatic acid: CT, clinical trial  
artificial tear: IT, drug interaction  
artificial tear: DT, drug therapy  
cevimeline: CT, clinical trial  
cevimeline: CM, drug comparison  
cevimeline: DT, drug therapy  
corticosteroid: AE, adverse drug reaction  
corticosteroid: DT, drug therapy  
corticosteroid: PD, pharmacology  
corticosteroid: TP, topical drug administration  
cyclosporin A: CT, clinical trial  
cyclosporin A: IT, drug interaction  
cyclosporin A: DT, drug therapy  
cyclosporin A: TP, topical drug administration  
diquafosol: CT, clinical trial  
diquafosol: DT, drug therapy  
diquafosol: PD, pharmacology  
diquafosol: TP, topical drug administration  
duramycin: CT, clinical trial  
estratest: CT, clinical trial  
estratest: DT, drug therapy  
estratest: TP, topical drug administration  
freshkote  
loteprednol etabonate: CT, clinical trial  
loteprednol etabonate: DT, drug therapy  
omega 3 fatty acid: DT, drug therapy  
pilocarpine: CM, drug comparison  
pilocarpine: DT, drug therapy  
rebamipide: CT, clinical trial  
rebamipide: DT, drug therapy  
rebamipide: TP, topical drug administration  
refresh endura  
restoryl  
soothe  
systane

**CAS REGISTRY NO.:**

(12 sulfodehydroabiatic acid) 33159-27-2, 86408-72-2;  
(cevimeline) 107220-27-9, 107220-28-0, 107233-08-9,  
153504-70-2; (cyclosporin A) 59865-13-3, 63798-73-2;  
(diquafosol) 211427-08-6; (duramycin) 1391-36-2;  
(loteprednol etabonate) 82034-46-6; (pilocarpine) 148-72-1,  
54-71-7, 92-13-7; (rebamipide)  
111911-87-6

**CHEMICAL NAME:**

(1) estratest; (2) evoxac; (3) freshkote; (4) moli 1901;  
(5) refresh endura; (6) restasis; (7) restoryl; (8)  
salagen; (9) soothe; (10) systane

**COMPANY NAME:**

(1) Solvay (United States); (2) Daiichi Seiyaku (United  
States); (3) Focus (United States); (4) lantibio (United  
States); (5) Allergen (United States); (6) Allergen (United  
States); (7) Bausch and Lomb (United States); (8) MGI  
(United States); (9) Bausch and Lomb (United States); (10)  
Alcon (United States); Inspire (United States); ISTA  
(United States); Otsuka (United States)

reserved on STN

ACCESSION NUMBER: 2008312479 EMBASE Full-text  
TITLE: Management and therapy of dry eye disease: Report  
of the management and therapy subcommittee of the  
international Dry Eye WorkShop (2007).  
AUTHOR: Pflugfelder, Stephen C., Dr. (correspondence)  
CORPORATE SOURCE: Ophthalmology-Ocular Surf Ctr., Cullen Eye Institute, 6565  
Fannin Street NC 205, Houston, TX 77030, United States.  
stevenp@bcm.tmc.edu  
AUTHOR: Lemp, Michael A.  
CORPORATE SOURCE: 4000 Cathedral Avenue NW, Washington, DC 20016, United  
States. malemp@lempdc.com  
AUTHOR: Geerling, Gerd; Kinoshita, Shigero; McCulley, James;  
Nelson, Daniel; Novack, Gary N.; Shimazaki, Jun; Wilson,  
Clive  
SOURCE: Ocular Surface, (Apr 2007) Vol. 5, No. 2, pp. 163-178.  
Refs: 185  
ISSN: 1542-0124  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)  
FILE SEGMENT: 012 Ophthalmology  
030 Clinical and Experimental Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles  
039 Pharmacy  
052 Toxicology  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 10 Jul 2008  
Last Updated on STN: 10 Jul 2008  
ABSTRACT: The members of the Management and Therapy Subcommittee assessed current dry  
eye therapies. Each member wrote a succinct evidence-based review  
on an assigned aspect of the topic, and the final report was written after  
review by and with consensus of all subcommittee members and the entire Dry Eye  
WorkShop membership. In addition to Its own review of the literature, the  
Subcommittee reviewed the Dry Eye Preferred Practice Patterns of the American  
Academy of Ophthalmology and the International Task Force (ITF) Delphi Panel on  
Dry Eye. The Subcommittee favored the approach taken by the ITF, whose  
recommended treatments were based on level of disease severity. The  
recommendations of the Subcommittee are based on a modification of the ITF  
severity grading scheme, and suggested treatments were chosen from a menu of  
therapies for which evidence of therapeutic effect had been presented.  
.COPYRGT. 2007 Ethis Communications, Inc.  
CONTROLLED TERM: Medical Descriptors:  
absence of side effects: SI, side effect  
autotransplantation  
blepharitis: DT, drug therapy  
burning sensation: SI, side effect  
clinical trial  
conference paper  
contact lens  
dose response  
drug dose comparison  
drug dose increase  
drug efficacy  
drug formulation  
drug mechanism  
drug megadose  
drug safety  
drug tolerability

**Serial#: 10/566,214**

drug withdrawal  
\*dry eye: DT, drug therapy  
\*dry eye: SU, surgery  
eye disease: SI, side effect  
human  
hyperhidrosis: SI, side effect  
keratoconjunctivitis sicca: DT, drug therapy  
low drug dose  
monotherapy  
nonhuman  
osmolarity  
rheumatoid arthritis: DT, drug therapy  
rosacea: DT, drug therapy  
salivary gland  
Schirmer test

Sjogren syndrome: DT, drug therapy  
systemic disease: SI, side effect  
tear film  
unspecified side effect: SI, side effect

**CONTROLLED TERM:**

Drug Descriptors:  
12 sulfodehydroabiatic acid: CT, clinical trial  
12 sulfodehydroabiatic acid: DT, drug therapy  
12 sulfodehydroabiatic acid: TP, topical drug administration  
15 hydroxyicosatetraenoic acid: DT, drug therapy  
15 hydroxyicosatetraenoic acid: PD, pharmacology  
15 hydroxyicosatetraenoic acid: TP, topical drug administration  
androgen: CT, clinical trial  
androgen: DT, drug therapy  
androgen: TP, topical drug administration  
angiogenesis inhibitor: DT, drug therapy  
antiinfective agent: DT, drug therapy  
antiinflammatory agent: DT, drug therapy  
artificial tear: CT, clinical trial  
artificial tear: CB, drug combination  
artificial tear: DT, drug therapy  
benzalkonium chloride: TO, drug toxicity  
cevimeline: AE, adverse drug reaction  
cevimeline: CT, clinical trial  
cevimeline: DO, drug dose  
cevimeline: DT, drug therapy  
cevimeline: PO, oral drug administration  
corticosteroid: CT, clinical trial  
corticosteroid: DT, drug therapy  
cyclosporin A: AE, adverse drug reaction  
cyclosporin A: CT, clinical trial  
cyclosporin A: DO, drug dose  
cyclosporin A: DT, drug therapy  
cyclosporin A: TP, topical drug administration  
de 089  
diquafosol: CT, clinical trial  
diquafosol: DT, drug therapy  
diquafosol: TP, topical drug administration  
doxycycline: CT, clinical trial  
doxycycline: DO, drug dose  
doxycycline: DT, drug therapy  
dwelle  
edetic acid: TO, drug toxicity  
endura  
essential fatty acid: CT, clinical trial



**Serial#: 10/566,214**

essential fatty acid: DT, drug therapy  
fluorometholone: CT, clinical trial  
fluorometholone: CB, drug combination  
fluorometholone: DT, drug therapy  
flurbiprofen: CT, clinical trial  
flurbiprofen: CB, drug combination  
flurbiprofen: DT, drug therapy  
gefarnate: DT, drug therapy  
gefarnate: TP, topical drug administration  
genteal  
hypotears: CT, clinical trial  
hypotears: DT, drug therapy  
hypotears: PR, pharmaceuticals  
hypotears pf  
loteprednol etabonate: CT, clinical trial  
loteprednol etabonate: DT, drug therapy  
methylprednisolone: AE, adverse drug reaction  
methylprednisolone: CT, clinical trial  
methylprednisolone: DT, drug therapy  
methylprednisolone: TP, topical drug administration  
minocycline: CT, clinical trial  
minocycline: DT, drug therapy  
optive  
pilocarpine: AE, adverse drug reaction  
pilocarpine: CT, clinical trial  
pilocarpine: DT, drug therapy  
pilocarpine: PO, oral drug administration  
placebo  
    rebamipide: CT, clinical trial  
    rebamipide: DT, drug therapy  
    rebamipide: PD, pharmacology  
    rebamipide: TP, topical drug administration  
refresh  
refresh free  
soothe  
systane  
tacrolimus: CT, clinical trial  
tacrolimus: DT, drug therapy  
tears natural free  
testosterone: CT, clinical trial  
testosterone: DT, drug therapy  
testosterone: TP, topical drug administration  
tetracycline derivative: CT, clinical trial  
tetracycline derivative: DT, drug therapy  
tetracycline derivative: PD, pharmacology  
tetryzoline: DT, drug therapy  
theratears  
unindexed drug  
visine pure tears

CAS REGISTRY NO.: (12 sulfodehydroabiatic acid) 33159-27-2, 86408-72-2; (15 hydroxyicosatetraenoic acid) 73180-00-4; (benzalkonium chloride) 66331-30-4, 78244-97-0, 81181-32-0; (cevimeline) 107220-27-9, 107220-28-0, 107233-08-9, 153504-70-2; (cyclosporin A) 59865-13-3, 63798-73-2; (diquafosol) 211427-08-6; (doxycycline) 10592-13-9, 17086-28-1, 564-25-0; (edetic acid) 150-43-6, 60-00-4; (essential fatty acid) 11006-87-4; (fluorometholone) 426-13-1; (flurbiprofen) 5104-49-4; (gefarnate) 51-77-4; (loteprednol etabonate) 82034-46-6; (methylprednisolone) 6923-42-8, 83-43-2; (minocycline) 10118-90-8, 11006-27-2, 13614-98-7; (pilocarpine) 148-72-1, 54-71-7, 92-13-7; (

**Serial#: 10/566,214**

rebamipide) 111911-87-6; (tacrolimus)  
104987-11-3; (testosterone) 58-22-0; (tetrazyoline)  
522-48-5, 84-22-0

CHEMICAL NAME: (1) de 089; (2) de 089; (3) dwelle; (4) endura; (5)  
genteal; (6) hypotears pf; (7) ins 365; (8) ins 365; (9)  
lotemax; (10) opc 12759; (11) opc 12759  
; (12) optive; (13) refresh free; (14) refresh; (15)  
soothe; (16) systane; (17) tears natural free; (18)  
theratears; (19) visine pure tears

COMPANY NAME: (1) Inspire (United States); (2) Santen (Japan); (3) Dry  
Eye (United States); (4) Allergan (United States); (5)  
Novartis (United States); (6) Novartis (United States); (7)  
Inspire (United States); (8) Santen (Japan); (9) Bausch and  
Lomb (United States); (10) Novartis (United States); (11)  
Otsuka (United States); (12) Allergan (United States); (13)  
Allergan (United States); (14) Allergan (United States);  
(15) Bausch and Lomb (United States); (16) Alcon (United  
States); (17) Alcon (United States); (18) Advanced Vision  
Research (United States); (19) Pfizer (United States);  
Senju (Japan)

**Serial#: 10/566,214**  
**SEARCH HISTORY**

FILE 'HCAPLUS' ENTERED AT 17:20:22 ON 20 NOV 2009  
E US2006-566214/APPS  
L1 2 SEA SPE=ON ABB=ON PLU=ON US2006-566214/APPS

FILE 'REGISTRY' ENTERED AT 17:21:52 ON 20 NOV 2009  
E 2-(4-CHLOROBENZOYLAMINO)-3-(2-QUINOLON-4-YL)PROPIONIC ACID/CN  
E 2-(4-CHLOROBENZOYLAMINO)-3-(2-QUINOLON-4-YL)PROPIONIC ACID/CN  
L2 STRUCTURE UPLOADED  
D  
L3 8 SEA SSS SAM L2  
L4 99 SEA SSS FUL L2  
L5 STRUCTURE UPLOADED  
D  
L6 4 SEA SUB=L4 SSS SAM L5  
L7 60 SEA SUB=L4 SSS FUL L5

FILE 'HCAPLUS' ENTERED AT 17:36:17 ON 20 NOV 2009  
L8 357 SEA SPE=ON ABB=ON PLU=ON L7

FILE 'REGISTRY' ENTERED AT 17:37:44 ON 20 NOV 2009  
L9 STRUCTURE UPLOADED  
D  
L10 54 SEA SUB=L7 SSS FUL L9  
L11 STRUCTURE UPLOADED  
D  
L12 48 SEA SUB=L7 SSS FUL L11  
L13 STRUCTURE UPLOADED  
D  
L14 35 SEA SUB=L7 SSS FUL L13

FILE 'HCAPLUS' ENTERED AT 17:45:01 ON 20 NOV 2009  
L15 356 SEA SPE=ON ABB=ON PLU=ON L14  
L16 57021 SEA SPE=ON ABB=ON PLU=ON SALIVA+PFT/CT OR SALIVA?/BI  
L17 11 SEA SPE=ON ABB=ON PLU=ON L16(L)ACCELERATION/OBI  
L18 1 SEA SPE=ON ABB=ON PLU=ON L15 AND L17  
L19 630 SEA SPE=ON ABB=ON PLU=ON XEROSTOMIA+OLD,PFT/CT  
L20 2 SEA SPE=ON ABB=ON PLU=ON L15 AND L19

FILE 'REGISTRY' ENTERED AT 17:49:15 ON 20 NOV 2009  
E 4-QUINOLINEPROPANOIC ACID, A-"((4-CHLOROBENZOYL)AMINO)"  
L21 1 SEA SPE=ON ABB=ON PLU=ON "4-QUINOLINEPROPANOIC ACID,  
A-((4-CHLOROBENZOYL)AMINO)-1,2-DIHYDRO-2-OXO-"/CN

FILE 'HCAPLUS' ENTERED AT 17:53:51 ON 20 NOV 2009  
L22 353 SEA SPE=ON ABB=ON PLU=ON L21  
L23 112 SEA SPE=ON ABB=ON PLU=ON NAGAMOTO H?/AU  
L24 78 SEA SPE=ON ABB=ON PLU=ON KOHASHI M?/AU  
L25 1964 SEA SPE=ON ABB=ON PLU=ON OKA H?/AU  
L26 3 SEA SPE=ON ABB=ON PLU=ON L15 AND L16  
L27 3 SEA SPE=ON ABB=ON PLU=ON L18 OR L20 OR L26  
L28 3 SEA SPE=ON ABB=ON PLU=ON L27 AND ((L23 OR L24 OR L25))  
L29 1 SEA SPE=ON ABB=ON PLU=ON L23 AND L24 AND L25  
L30 3 SEA SPE=ON ABB=ON PLU=ON L28 OR L29

FILE 'REGISTRY' ENTERED AT 17:57:08 ON 20 NOV 2009  
SET SMARTSELECT ON  
L31 SEL PLU=ON L21 1- NAME : 4 TERMS  
SET SMARTSELECT OFF

**Serial#: 10/566,214**

FILE 'MEDLINE' ENTERED AT 17:57:08 ON 20 NOV 2009  
L32 228 SEA SPE=ON ABB=ON PLU=ON L31  
L33 228 SEA SPE=ON ABB=ON PLU=ON L21 OR L32  
L34 26444 SEA SPE=ON ABB=ON PLU=ON SALIVA/CT  
L35 5906 SEA SPE=ON ABB=ON PLU=ON ACCELERATION/CT  
L36 4 SEA SPE=ON ABB=ON PLU=ON L34 AND L35  
L37 3041 SEA SPE=ON ABB=ON PLU=ON XEROSTOMIA/CT  
L38 0 SEA SPE=ON ABB=ON PLU=ON L33 AND L36 AND L37  
L39 0 SEA SPE=ON ABB=ON PLU=ON L33 AND L36  
L40 1 SEA SPE=ON ABB=ON PLU=ON L33 AND L37  
L41 1 SEA SPE=ON ABB=ON PLU=ON L33 AND L34  
L42 1 SEA SPE=ON ABB=ON PLU=ON L40 OR L41  
L43 8594 SEA SPE=ON ABB=ON PLU=ON "SJOGREN'S SYNDROME"/CT  
L44 3 SEA SPE=ON ABB=ON PLU=ON L33 AND L43  
L45 3 SEA SPE=ON ABB=ON PLU=ON L42 OR L44  
L46 34 SEA SPE=ON ABB=ON PLU=ON NAGAMOTO H?/AU  
L47 19 SEA SPE=ON ABB=ON PLU=ON KOHASHI M?/AU  
L48 932 SEA SPE=ON ABB=ON PLU=ON OKA H?/AU  
L49 0 SEA SPE=ON ABB=ON PLU=ON L46 AND L47 AND L48  
L50 2 SEA SPE=ON ABB=ON PLU=ON L45 AND ((L46 OR L47 OR L48))

FILE 'HCAPLUS' ENTERED AT 18:08:01 ON 20 NOV 2009  
L51 3703 SEA SPE=ON ABB=ON PLU=ON SJOGREN SYNDROME+OLD,PFT/CT  
L52 4 SEA SPE=ON ABB=ON PLU=ON L15 AND L51  
L53 4 SEA SPE=ON ABB=ON PLU=ON L27 OR L52

FILE 'REGISTRY' ENTERED AT 18:10:25 ON 20 NOV 2009  
SET SMARTSELECT ON  
L54 SEL PLU=ON L21 1- NAME : 4 TERMS  
SET SMARTSELECT OFF

FILE 'WPIX, BIOSIS' ENTERED AT 18:10:26 ON 20 NOV 2009  
L55 379 SEA SPE=ON ABB=ON PLU=ON L54  
L56 379 SEA SPE=ON ABB=ON PLU=ON L21 OR L55  
L57 3824 SEA SPE=ON ABB=ON PLU=ON SALIVA?(10A) (ACCEL? OR INCREAS?)  
L58 0 SEA SPE=ON ABB=ON PLU=ON L56 AND L57  
L59 0 SEA SPE=ON ABB=ON PLU=ON L56(P) L57  
L60 0 SEA SPE=ON ABB=ON PLU=ON L56(30A) L57  
L61 4470 SEA SPE=ON ABB=ON PLU=ON XEROSTO? OR DRY(3A) MOUTH?  
L62 0 SEA SPE=ON ABB=ON PLU=ON L56 AND L61  
L63 0 SEA SPE=ON ABB=ON PLU=ON L56(30A) L61  
L64 82 SEA SPE=ON ABB=ON PLU=ON NAGAMOTO H?/AU  
L65 73 SEA SPE=ON ABB=ON PLU=ON KOHASHI M?/AU  
L66 3368 SEA SPE=ON ABB=ON PLU=ON OKA H?/AU  
L67 1 SEA SPE=ON ABB=ON PLU=ON L64 AND L65 AND L66

FILE 'REGISTRY' ENTERED AT 18:18:27 ON 20 NOV 2009  
SET SMARTSELECT ON  
L68 SEL PLU=ON L21 1- NAME : 4 TERMS  
SET SMARTSELECT OFF

FILE 'EMBASE' ENTERED AT 18:18:28 ON 20 NOV 2009  
L69 381 SEA SPE=ON ABB=ON PLU=ON L68  
L70 381 SEA SPE=ON ABB=ON PLU=ON L21 OR L69  
L71 17167 SEA SPE=ON ABB=ON PLU=ON XEROSTOMIA/CT  
L72 9448 SEA SPE=ON ABB=ON PLU=ON SJOEGREN SYNDROME/CT  
L73 7904 SEA SPE=ON ABB=ON PLU=ON SALIVA/CT  
L74 7 SEA SPE=ON ABB=ON PLU=ON L70 AND L71  
L75 12 SEA SPE=ON ABB=ON PLU=ON L70 AND L72  
L76 0 SEA SPE=ON ABB=ON PLU=ON L70 AND L73

**Serial#: 10/566,214**

L77 2 SEA SPE=ON ABB=ON PLU=ON L75 AND MANAGEMENT/TI  
L78 5 SEA SPE=ON ABB=ON PLU=ON L75 NOT (EYE OR RHEUMATOLOGIC)/TI  
L79 7 SEA SPE=ON ABB=ON PLU=ON L77 OR L78  
L80 9 SEA SPE=ON ABB=ON PLU=ON L74 OR L79  
L81 35 SEA SPE=ON ABB=ON PLU=ON NAGAMOTO H?/AU  
L82 15 SEA SPE=ON ABB=ON PLU=ON KOHASHI M?/AU  
L83 863 SEA SPE=ON ABB=ON PLU=ON OKA H?/AU  
L84 0 SEA SPE=ON ABB=ON PLU=ON L81 AND L82 AND L83  
L85 2 SEA SPE=ON ABB=ON PLU=ON L80 AND (L81 OR L82 OR L83)

FILE 'REGISTRY' ENTERED AT 18:31:38 ON 20 NOV 2009

FILE 'HCAPLUS' ENTERED AT 18:31:46 ON 20 NOV 2009  
D STAT QUE L30

FILE 'MEDLINE' ENTERED AT 18:32:00 ON 20 NOV 2009  
D STAT QUE L50

FILE 'WPIX, BIOSIS' ENTERED AT 18:32:54 ON 20 NOV 2009  
D STAT QUE L67

FILE 'EMBASE' ENTERED AT 18:33:02 ON 20 NOV 2009  
D STAT QUE L85

L86 FILE 'HCAPLUS, MEDLINE, WPIX, EMBASE' ENTERED AT 18:33:28 ON 20 NOV 2009  
3 DUP REMOVE L30 L50 L67 L85 (5 DUPLICATES REMOVED)  
ANSWERS '1-3' FROM FILE HCAPLUS  
D L86 IBIB ABS HITSTR 1-3

FILE 'HCAPLUS' ENTERED AT 18:33:53 ON 20 NOV 2009  
D STAT QUE L53

FILE 'MEDLINE' ENTERED AT 18:34:11 ON 20 NOV 2009

L87 FILE 'HCAPLUS' ENTERED AT 18:34:19 ON 20 NOV 2009  
1 SEA SPE=ON ABB=ON PLU=ON L53 NOT L30

FILE 'MEDLINE' ENTERED AT 18:34:42 ON 20 NOV 2009  
D STAT QUE L45  
L88 1 SEA SPE=ON ABB=ON PLU=ON L45 NOT L50

FILE 'WPIX, BIOSIS' ENTERED AT 18:35:23 ON 20 NOV 2009  
D STAT QUE L60  
D STAT QUE L62


FILE 'EMBASE' ENTERED AT 18:35:44 ON 20 NOV 2009  
D STAT QUE L80  
L89 7 SEA SPE=ON ABB=ON PLU=ON L80 NOT L85

L90 FILE 'HCAPLUS, MEDLINE, EMBASE' ENTERED AT 18:36:18 ON 20 NOV 2009  
8 DUP REMOVE L87 L88 L89 (1 DUPLICATE REMOVED)  
ANSWER '1' FROM FILE HCAPLUS  
ANSWER '2' FROM FILE MEDLINE  
ANSWERS '3-8' FROM FILE EMBASE

=>

Serial#: 10/566,214

Uploading L2.str




```
chain nodes :
11 12 13 14 15 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 16 17 18 19 20 21
chain bonds :
8-13 10-11 11-12 12-14 14-15 15-16 15-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 16-17 16-21 17-18 18-19
19-20 20-21
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 8-13 9-10 10-11 11-12 12-14
14-15 15-16 15-22 16-17 16-21 17-18 18-19 19-20 20-21
```

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:CLASS
```

Uploading L5.str

Serial#: 10/566,214



```

chain nodes :
11 12 13 14 15 22 23 24 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 16 17 18 19 20 21
chain bonds :
8-13 10-11 11-12 12-14 12-23 14-15 15-16 15-22 19-26 23-24 23-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 16-17 16-21 17-18 18-19
19-20 20-21
exact/norm bonds :
5-7 6-10 7-8 8-9 8-13 9-10 12-14 14-15 15-22 23-24 23-25
exact bonds :
10-11 11-12 12-23 15-16 19-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21


```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS

```

Uploading L13.str



chain nodes :

11 12 13 14 15 22 23 24 25 26

ring nodes :

1 2 3 4 5 6 7 8 9 10 16 17 18 19 20 21

chain bonds :

8-13 10-11 11-12 12-14 12-23 14-15 15-16 15-22 19-26 23-24 23-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 16-17 16-21 17-18 18-19 19-20 20-21

exact/norm bonds :

5-7 6-10 7-8 8-9 8-13 9-10 12-14 14-15 15-22

exact bonds :

10-11 11-12 12-23 15-16 19-26

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21 23-24 23-25

Connectivity :



**Serial#: 10/566,214**

12:3 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom

20:Atom 21:Atom

22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS